Trial
NCT04974944
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sun Yat-Sen University Cancer Center
Collaborators
—
Condition
Stage IVB Cervical Cancer
Intervention
Camrelizumab
Why stopped
No superior PFS in study group among the enrolled patients. Company R\&D strategy shifted; funding discontinued, study terminated.
Provenance
Dataset: 2026-07-31 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-29